SEHK:1672Biotechs
Is Stock Connect Access Altering The Investment Case For Ascletis Pharma (SEHK:1672)?
Ascletis Pharma reported a CNY 319.67 million net loss for the half year to June 30, 2026, while also advancing ASC30 into global Phase III trials for chronic weight management and diabetes across the U.S., Europe, and Canada.
The firm’s inclusion in both the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs from September 7, 2026, opens its shares to a wider Mainland China investor pool and may influence how funding for its obesity portfolio is perceived.
With Ascletis Pharma...